Trials / Recruiting
RecruitingNCT07302360
A Real-World Study of Guselkumab in Chinese Participants With Ulcerative Colitis
Guselkumab Real-world Effectiveness Among Bio-NaÏve Patients With Moderate-to-severe Ulcerative Colitis in China: A Multicenter, Non-interventional, Prospective Study
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 200 (estimated)
- Sponsor
- Xian-Janssen Pharmaceutical Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess the measurable changes in health, function, or quality of life (clinical outcomes) after receiving guselkumab in real-world clinical practice amongst Chinese participants with ulcerative colitis (UC; a long-term disease of the large intestine in which the lining of the colon \[part of large intestine\] becomes inflamed and develops tiny open ulcers), who have not received biologic therapy (a medicine made from living organisms or their components) previously.
Conditions
Timeline
- Start date
- 2025-12-15
- Primary completion
- 2028-06-30
- Completion
- 2028-06-30
- First posted
- 2025-12-24
- Last updated
- 2026-04-13
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT07302360. Inclusion in this directory is not an endorsement.